[1] Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine, 2009, 27:6550-6557. [2] Ge J, Wang K, Meng Q, et al. Implication of Th17 and Th1 cells in patients with chronic active Hepatitis B. J Clin Immunol, 2010, 30:60-67. [3] 孙静美, 董志鹏, 杨自坚, 等.乙型肝炎患者病情严重程度与其免疫状态的关系分析. 哈尔滨医药, 2018, 38:413-414. [4] 王贵强, 王福生, 成军,等.慢性乙型肝炎防治指南(2015版). 实用肝脏病杂志, 2016, 19:389-400. [5] Feng H, Yin J, Han YP, et al. Sustained changes of Treg and Th17 cells during interferon- α therapy in patients with chronic Hepatitis B. Viral Immunol, 2015, 28:412-417. [6] 于倩, 王晔恺, 姚燕珍, 等. 外周血白细胞介素-17及RORγt表达对恩替卡韦治疗慢性乙肝患者疗效的预测价值. 中国卫生检验杂志, 2018, 28:694-696,699. [7] 龙玲, 姚云清, 汪燕, 等. 恩替卡韦治疗慢性乙型肝炎病毒携带者疗效的免疫学观察. 重庆医科大学学报, 2018, 43:961-968. [8] 郭如意, 余雪平, 黄绿叶, 等.慢性乙型肝炎患者核苷(酸)类似物治疗前后外周血中Treg和Th17细胞及其相关细胞因子水平的变化. 中华微生物学和免疫学杂志, 2013, 33:216-221. [9] Wang Y, Yang S, Su C, et al. Predictors of response to pegylated interferon in chronic hepatitis B: a real-world hospital-based analysis. Sci Rep, 2016, 6:29605. [10] 邵春丽, 邓国伟, 金国贤.慢性乙型肝炎外周血单个核细胞与血清中TOⅡ样受体及Th1/Th2/Th17型细胞因子的表达. 中国临床医生杂志, 2016, 44:39-42. |